ICOS

ICOS 분자 정보

영어 이름Inducible T-cell costimulator시판 약물 수0
임상 약물 수7표적 별명Activation-inducible lymphocyte immunomediatory molecule,Inducible T-cell costimulator,ICOS,CD278,AILIM,Inducible T Cell Costimulator,Inducible T-Cell Co-Stimulator,Inducible Costimulator,CD278 Antigen,CVID1,Inducible T-Cell Co-Stimulator Protein
최고 연구 개발 단계Phase 2 Clinical
영어 이름Inducible T-cell costimulator
표적 별명Activation-inducible lymphocyte immunomediatory molecule,Inducible T-cell costimulator,ICOS,CD278,AILIM,Inducible T Cell Costimulator,Inducible T-Cell Co-Stimulator,Inducible Costimulator,CD278 Antigen,CVID1,Inducible T-Cell Co-Stimulator Protein
시판 약물 수0
임상 약물 수7
최고 연구 개발 단계Phase 2 Clinical

ICOS 제품 목록

  • 속성

    Protein (6)

  • 제품 라이브러리

    온라인 (6)

  • Human (3)Mouse (2)Rat (1)

  • 태그

    His Tag & Avi Tag (1)Fc Tag (2)His Tag (3)

  • 마커

    Biotin-labeled (1)Unconjugated (5)

ICOS분자 배경

Inducible T-cell costimulator (ICOS) is also known as Activation-inducible lymphocyte immunomediatory molecule (AILIM), CD278, which belongs to the CD28 family of immune costimulatory receptors consisting of CD28, CTLA-4 and PD-1. ICOS enhances all basic T-cell responses to a foreign antigen, namely proliferation, secretion of lymphokines, up-regulation of molecules that mediate cell-cell interaction, and effective help for antibody secretion by B-cells. CD278 / ICOS prevents the apoptosis of pre-activated T-cells and also plays a critical role in CD40-mediated class switching of immunoglobin isotypes.

ICOS분자 별명

ICOS,CD278,AILIM,Inducible T-cell costimulator

임상 약물 정보

영어 이름연구 코드연구 개발 단계회사적응증임상 시험
VopratelimabJTX-2011Phase 2 ClinicalJounce Therapeutics IncCarcinoma, Non-Small-Cell Lung; Neoplasms
상세
FeladilimabGSK-609; GSK-3359609Phase 2 ClinicalGlaxosmithkline PlcHead and Neck Neoplasms; Multiple Myeloma; Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck
상세
AcazicolceptALPN-101Phase 2 ClinicalAlpine Immune Sciences IncAutoimmune Diseases; Graft vs Host Disease; Inflammation; Lupus Erythematosus, Systemic; Lymphoproliferative Disorders
상세
MEDI-570Phase 1 ClinicalJapan Tobacco (Hong Kong) LtdLupus Erythematosus, Systemic; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Lymphoma, T-Cell, Cutaneous; Mycosis Fungoides
상세
IzuralimabXmAb-23104; XmAb-104Phase 1 ClinicalXencor IncCarcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Colorectal Neoplasms; Endometrial Neoplasms; Gastroesophageal Junction Neoplasms; Melanoma; Nasopharyngeal Carcinoma; Pancreatic Neoplasms; Sarcoma; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms; Uterine Cervical Neoplasms
상세
Anti-ICOS (Bristol Myers Squibb)BMS-986226Phase 1 ClinicalBristol-Myers Squibb CompanyNeoplasms
상세
anti-ICOS mAb (Bristol-Myers Squibb)Phase 1 ClinicalBristol-Myers Squibb CompanyNeoplasms; Solid tumours
상세
  • 분자 정보
  • 제품 목록
  • 임상 약물 정보
문의하기

전화
글로벌: +1 800-810-0816 (무료)
아시아태평양: +86 400-682-2521

주소 서울특별시 송파구 법원로11길 11, 제3층 제비-314,315호